A CKAAKN peptide-conjugated nanoliposome selectively delivered the anti-cancer compound oridonin to pancreatic cancer cells, showing enhanced tumor uptake and significantly improved antitumor effects in vitro and in vivo.
Selective tumor uptake over 48 hoursCKAAKN peptide-conjugated nanoliposomes accumulated preferentially in pancreatic tumors versus normal tissue, with increasing ratios over time
What the researchers found
The CKAAKN peptide-conjugated nanoliposome (ORI@CPD-Lipo) demonstrated:
- Average particle size of ~100 nm with good stability and biosafety
- Selective internalization into BxPC-3 pancreatic cancer cells within 1–4 hours in vitro, compared to minimal uptake in normal HPDE6-C7 cells
- Significantly higher tumor uptake in vivo over 1–48 hours compared to normal pancreatic tissue, with increasing ratios over time
- Enhanced antitumor effect compared to free oridonin, non-targeting liposomes, and CKAAKN-blocked controls
- The enhanced activity was attributed to peptide-mediated cellular uptake and sustained drug release from nanoparticles
Why it matters
Pancreatic cancer has one of the worst survival rates of any cancer, partly because drugs don't reach the tumor effectively. Using a targeting peptide to guide drug-loaded nanoparticles directly to cancer cells could significantly improve treatment efficacy while reducing side effects from off-target drug exposure. This peptide-targeted approach is applicable beyond oridonin to other anti-cancer agents.
How the study worked
Researchers developed PEGylated nanoliposomes modified with the CKAAKN tumor-targeting peptide to deliver oridonin. The formulation was characterized for size, stability, and safety. In vitro studies compared uptake in pancreatic cancer cells (BxPC-3) versus normal cells (HPDE6-C7). In vivo biodistribution was assessed in tumor-bearing mice. Antitumor efficacy was compared across free drug, non-targeting liposomes, targeted liposomes, and CKAAKN-blocked controls.
What this study cannot tell us
This is a preclinical study using cell lines and mouse xenograft models, which may not fully reflect human pancreatic cancer complexity. The oridonin payload is a natural compound with limited clinical validation. Long-term safety, pharmacokinetics, and potential immunogenicity of the peptide-conjugated nanoliposomes in humans are unknown. Manufacturing scalability of the targeted nanoformulation was not addressed.
How to read the evidence
This is a preclinical study with in vitro cell culture and in vivo mouse xenograft data. While it demonstrates proof-of-concept for peptide-targeted delivery, no human testing has been conducted.
When this study was published
Published in 2026, this is very recent work in the active field of peptide-targeted cancer nanomedicine.
The bigger picture
Peptide-targeted drug delivery is an active area of cancer nanotechnology research. The CKAAKN peptide specifically recognizes pancreatic cancer cells, making it a valuable targeting ligand. This study demonstrates the viability of combining targeting peptides with nanoliposome technology to improve chemotherapy delivery, an approach being explored for multiple cancer types.
Questions still open
- Could CKAAKN peptide-targeted nanoliposomes deliver more established chemotherapy drugs like gemcitabine to pancreatic tumors?
- How does the immune system respond to repeated administration of peptide-conjugated nanoliposomes?
- What is the maximum therapeutic index improvement achievable with peptide-targeted versus untargeted drug delivery in pancreatic cancer?
Common questions
How does the CKAAKN peptide target pancreatic cancer?
Could this approach work for other types of cancer?
Read the original research
CKAAKN peptide-conjugated long-circulating nanoliposomes for the targeted delivery of oridonin to pancreatic cancers.
Scientific reports, 16(1), 6065
Citation
Zhang, Fangxia; Luo, Kunshun; Xuan, Shaoyan; Chen, Teng; Chen, Zhiyong; Yang, Jing; Zhou, Ying; Feng, Tingting; Zhu, Yue; Wang, Zuhua. (2026). CKAAKN peptide-conjugated long-circulating nanoliposomes for the targeted delivery of oridonin to pancreatic cancers.. Scientific reports, 16(1), 6065. https://doi.org/10.1038/s41598-026-36920-5